2. Search Result
Search Result
Results for "

CC-chemokine

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Inhibitory Antibodies

11

Protéines recombinantes

3

Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Nom du produit Target Áreas de investigación Chemical Structure
  • HY-103364A
    C-021 dihydrochloride
    2 Publications Verification

    		 CCR Inflammation/Immunology
    C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [ 35S]GTPγS from binding to the receptor with an IC50 of 18 nM .
    C-021 dihydrochloride
  • HY-P99188
    Carlumab
    4 Publications Verification

    CNTO 888

    		 CCR Cancer
    Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) monoclonal antibody. Carlumab binds and neutralises profibrotic activities of human CCL2. Carlumab inhibits tumor growth by reducing macrophage infiltration and decreasing tumor microvascular density. Carlumab can be used for the research of cancer, suah as prostate cancer .
    Carlumab
  • HY-U00064
    AZD2098
    4 Publications Verification

    		 CCR Inflammation/Immunology Endocrinology
    AZD2098 is a potent and selective CC-chemokine receptor 4 (CCR4) inhibitor with pIC50s of 7.8, 8.0, 8.0 and 7.6 for human, rat, mouse and dog respectively, used for asthma research .
    AZD2098
  • HY-133073
    CCR7 Ligand 1
    3 Publications Verification

    CCR7-Cmp2105

    		 CCR Ligands for Target Protein for PROTAC Cancer
    CCR7 Ligand 1 (CCR7-Cmp2105) is an allosteric Ligand and antagonist for human CC chemokine receptor 7 (CCR7) with a Kd of 3 nM. CCR7 Ligand 1, thiadiazole-dioxide ligan, suppresses arrestin binding in response to activation by CCL19 with an IC50 of 7.3 μM .
    CCR7 Ligand 1
  • HY-100183
    GSK2239633A

    		CCR Inflammation/Immunology Endocrinology
    GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [ 125I]-TARC to human CCR4 with a pIC50 of 7.96.
    GSK2239633A
  • HY-101038A
    ZK756326 dihydrochloride
    1 Publications Verification

    		 CCR Endocrinology Cancer
    ZK756326 dihydrochloride is a nonpeptide chemokine receptor agonist for the CC chemokine receptor CCR8.
    ZK756326 dihydrochloride
  • HY-103364
    C-021
    2 Publications Verification

    		 CCR Inflammation/Immunology
    C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [ 35S]GTPγS from binding to the receptor with an IC50 of 18 nM .
    C-021
  • HY-121885
    LMD-009
    2 Publications Verification

    		 CCR Metabolic Disease Endocrinology
    LMD-009 is a selective CCR8 nonpeptide agonist. LMD-009 mediates chemotaxis, inositol phosphate accumulation, and calcium release in high potencies with EC50s from 11 to 87 nM .
    LMD-009
  • HY-157453
    CCR4 antagonist 4
    1 Publications Verification

    		 CCR Inflammation/Immunology
    CCR4 antagonist 4 (compound 22) is a selective and potent antagonist of the CC chemokine receptor-4 (CCR4), with an IC50 of 0.02 μM. CCR4 antagonist 4 also blocks MDC-mediated chemotaxis (IC50: 0.007 μM) and Ca 2+ mobilization (IC50: 0.003 μM). CCR4 antagonist 4 can be used for allergic inflammation research .
    CCR4 antagonist 4
  • HY-112874
    BMS-681

    BMS-687681

    		 CCR Neurological Disease Inflammation/Immunology Cancer
    BMS-681 is an orthosteric antagonist of CC chemokine receptor 2 (CCR2). BMS-681 restricts the movement of the extracellular end of TM6 by stabilizing TM7. TM7 and TM6 are the main components of the orthosteric binding site. BMS-681 can be used to study inflammatory neurodegenerative diseases and cancer .
    BMS-681
  • HY-101038
    ZK 756326

    		CCR Endocrinology Cancer
    ZK756326 is a nonpeptide chemokine receptor agonist for the CC chemokine receptor CCR8.
    ZK 756326
  • HY-176980
    CCR6 antagonist 4

    		CCR Inflammation/Immunology
    CCR6 antagonist 4 (compound OXM1) is a potent and selective CC chemokine receptor 6 (CCR6) allosteric antagonist (IC50 = 158 nM). CCR6 antagonist 4 binds to an extracellular pocket and disrupts the receptor activation network. CCR6 antagonist 4 can be used for chronic inflammatory diseases research .
    CCR6 antagonist 4
  • HY-176979
    CCR6 antagonist 3

    		CCR Inflammation/Immunology
    CCR6 antagonist 3 (compound OXM2) is a potent and selective CC chemokine receptor 6 (CCR6) allosteric antagonist (IC50 = 166 nM). CCR6 antagonist 3 binds to an extracellular pocket and disrupts the receptor activation network. CCR6 antagonist 3 can be used for chronic inflammatory diseases research .
    CCR6 antagonist 3
  • HY-125836
    CCR4 antagonist 2

    		CCR Endocrinology Cancer
    CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC50 values of Ca 2+flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively .
    CCR4 antagonist 2
  • HY-163761
    LT166

    		CCR Others
    LT166 is a fluorescent ligand for CC chemokine receptor 1 (CCR1) with a KD of 1.90 μM .
    LT166
  • HY-103364AR
    C-021 dihydrochloride (Standard)

    		Reference Standards CCR Inflammation/Immunology
    C-021 (dihydrochloride) (Standard) is the analytical standard of C-021 (dihydrochloride). This product is intended for research and analytical applications. C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [35S]GTPγS from binding to the receptor with an IC50 of 18 nM .
    C-021 dihydrochloride (Standard)
  • HY-103364R
    C-021 (Standard)

    		Reference Standards CCR Inflammation/Immunology
    C-021 (Standard) is the analytical standard of C-021. This product is intended for research and analytical applications. C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [35S]GTPγS from binding to the receptor with an IC50 of 18 nM .
    C-021 (Standard)
  • HY-174744
    Human CCR4 mRNA

    		mRNA Inflammation/Immunology
    Human CCR4 mRNA encodes the human C-C motif chemokine receptor 4 (CCR4) protein, a member of G protein-coupled receptors family. CCR4 is a receptor for the CC chemokine - MIP-1, RANTES, TARC and MCP-1. Chemokines are a group of small polypeptide, structurally related molecules that regulate cell trafficking of various types of leukocytes. The chemokines also play fundamental roles in the development, homeostasis, and function of the immune system, and they have effects on cells of the central nervous system as well as on endothelial cells involved in angiogenesis or angiostasis.
    Human CCR4 mRNA
  • HY-100183R
    GSK2239633A (Standard)

    		CCR Reference Standards Inflammation/Immunology Endocrinology
    GSK2239633A (Standard) is the analytical standard of GSK2239633A (HY-100183). This product is intended for research and analytical applications. GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96.
    GSK2239633A (Standard)
  • HY-182564
    ST45177901

    		CCR Cancer
    ST45177901 is a CC chemokine receptor 4 (CCR4) antagonist. The combination of ST45177901 and Sorafenib (HY-10201) effectively inhibits the chemotaxis of Treg cells via the CCL22/CCL17-CCR4 signaling pathway, thereby significantly suppressing the growth and metastasis of tumor cells. ST45177901 is applicable to liver cancer research .
    ST45177901

Demande en ligne

Your information is safe with us. * Required Fields.

Civilité

  

Country or Region *

Nom du demandeur *

 

Nom de l'organisation *

Department *

     

Adresse e-mail *

 

Nom du produit *

Cat. No.

  

Requested quantity *

Numéro de téléphone *

     

Remarques

Demande en ligne

Inquiry Information

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent: